Insmed Inc (INSM) Peer Comparison

$112.58

$0.99 (0.89%)

As on 30-Oct-2026 16:00EST

Market cap

$24,698 Mln

Revenue (TTM)

$1,520 Mln

P/E Ratio

--

P/B Ratio

34

Div. Yield

0 %

Edit

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Market cap ($ Mln)	24,698	95,531	44,890	22,100	18,238
Revenue ($ Mln)	1,520	16,896	17,311	5,013	2,838
Net Profit ($ Mln)	-605.61	4,817.40	1,394.00	2,724.24	517.83
Net Margin (%)	-39.85	28.51	8.05	54.34	18.24
RoE (%)	-84.64	14.84	21.57	116.44	87.53
Price to Earnings	--	23.24	33.14	8.33	36.20
Price-To-Book	34.01	2.87	6.81	6.13	31.17

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Operating Revenue	1,519.72	16,896.20	17,311.00	5,013.24	2,838.39
Cost of Revenue	239.15	2,404.10	12,731.00	1,138.86	2,011.22
Gross Profit	481.55	12,242.20	5,430.00	3,036.77	760.62
Operating Expenses	1,821.48	9,500.60	2,256.00	2,896.79	220.03
Operating Profit (EBIT)	-540.91	4,991.50	2,324.00	977.59	607.14
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-598.06	5,686.80	1,629.00	856.41	626.99
Provision for Tax	7.55	869.40	253.00	-1,899.16	109.17
Profit after Tax (Net Income)	-605.61	4,817.40	1,394.00	2,724.24	517.83
Minority Interest	0.00	0.00	-5.00	0.00	0.00
Consolidated Profit	0.00	0.00	514.00	0.00	0.00

Liabilities ($ Mln)

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Shareholder's Funds	726.21	33,498.50	6,660.00	3,603.85	584.94
Minority Interest	0.00	0.00	-5.00	0.00	0.00
Non-Current Liabilities	903.27	4,704.60	15,906.00	2,327.81	221.56
Current Liabilities	596.58	6,202.10	7,777.00	2,063.01	1,496.10
Total Liabilities	2,264.56	40,558.70	29,944.00	4,966.33	1,975.47

Assets ($ Mln)

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Non-Current Assets	519.55	23,610.10	24,023.00	2,882.01	1,057.60
Current Assets	1,706.51	20,795.10	6,451.00	5,112.66	1,245.00
Total Assets	2,264.56	40,558.70	29,944.00	4,966.33	1,975.47
Total Debt*	741.17	2,707.00	16,314.00	1,261.99	146.04
Net Current Assets	1,109.93	0.00	-1,326.00	3,049.66	-251.10

Cashflow ($ Mln)

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Cash From Operating Activities	-935.01	4,978.90	2,654.00	524.08	713.22
Cash Flow from Investing Activities	-64.58	-629.10	-2,305.00	436.33	-31.14
Cash from Financing Activities	954.07	-3,715.40	-150.00	-305.19	-860.39
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
ROCE (%)	-82.20	13.65	6.34	18.29	57.43
ROE (%)	-84.64	14.84	21.57	116.44	87.53
ROA (%)	-21.63	8.78	3.69	33.09	15.15
EBIT Margin (%)	-34.09	33.93	13.74	23.79	21.70
Net Margin (%)	-39.85	28.51	8.05	54.34	18.24
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Revenue Growth (%)	239.97	18.59	8.85	56.17	20.35
EBIT Growth (%)	52.94	10.53	3.21	815.27	18.61
Net Profit Growth (%)	48.84	5.23	8.65	6,153.27	19.59
EPS Growth (%)	54.46	8.23	12.82	8,782.16	28.06
Book Value Growth (%)	-25.78	9.85	11.16	1,433.08	108.60

Valuation Ratios

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Price / Earnings	-29.12	18.42	28.49	172.73	36.06
Price / Book Value	34.01	2.87	6.81	6.13	31.17
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-48.66	14.35	16.38	16.40	27.78
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Debt to Equity	0.75	0.00	2.23	0.18	0.00
Short term debt to equity ratio	0.03	0.02	0.19	0.11	0.00
Current Ratio	2.86	3.35	0.83	2.48	0.83
Quick Ratio	2.59	2.89	0.83	2.43	0.83
Interest Coverage	-6.35	122.77	3.08	3.35	--

Operating Efficiency Ratios

	Insmed Inc (INSM)	Regeneron Pharmaceuticals (REGN)	IQVIA Holdings (IQV)	Alnylam Pharmaceuticals (ALNY)	Medpace Holdings (MEDP)
Debtors to sales (%)	17.06	44.85	19.25	21.64	15.77
Asset Turnover	0.54	0.31	0.46	0.61	0.83
Receivable days	58.08	152.19	74.65	58.17	50.42
Inventory Days	337.31	546.66	--	43.48	--
Payable days	223.67	150.27	75.32	55.05	6.26
Cash Conversion Cycle	171.72	548.59	--	46.59	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly